Aurinia Pharmaceuticals’ Upcoming Q4 Earnings Preview 
<p>RBC Capital analysts provided their outlook on <a href='https://financialmodelingprep.com/financial-summary/AUPH'>Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)</a> ahead of the upcoming Q4 earnings, expected to be released on Tuesday.</p>
<p>The company announced preliminary Q4/22 revenues of $28.4 million that were ahead of Street estimates. Management expects LUPKYNIS net revenue in the range of $120-140 million in 2023 (vs. Street’s estimate of $136.5 million). </p>
<p>The analysts expect the focus to remain on LUPKYNIS growth and ring-fencing opportunities around the dosing patent. The management team holds the belief that the new patent application '140 has the capability to offer extra patent coverage for LUPKYNIS until 2037.</p>
<p>The analyst reiterated their Outperform - Speculative Risk rating on the stock with a price target of $11.</p>

NASDAQ:AUPH